NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 59.32

+2.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: zax	5/14/2009 10:46:18 AM
	Read Replies (1) of 507

Cimzia Approved for RA!!! Next stop, the BANK. 9:49AM Nektar Therapeutics announces UCB's Cimzia approved by U.S. FDA for adult patients suffering from moderate to severe Rheumatoid Arthritis (NKTR) 5.60 +0.45 : Co confirms UCB's announcement that the US Food and Drug Administration (FDA) has approved Cimzia (certolizumab pegol), the only PEGylated anti-TNFa (Tumor Necrosis Factor alpha), for the treatment of adult patients with moderately to severely active rheumatoid arthritis. Under the terms of the agreement between Nektar and UCB, Nektar receives manufacturing revenues during research, clinical development, and commercialization of Cimzia. Nektar also receives royalties on end product sales.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next